ClinicalTrials.gg
Not yet recruitingNCT07944365PIRATEUpdated Nov 18, 2026

Plasma Pyrophosphate Imbalance According to Phenotype and Bone Remodelling Alterations in Type 1 Neurofibromatosis - PIRATE-NF1 -

An observational study in Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (NFP), sponsored by University Hospital, Angers. Not yet recruiting. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University Hospital, Angers · Observational

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years to 100 Years
Sex
All
01

Study summary

Neurofibromatosis type 1 (NF1) is a multisystemic genetic disorder associated with frequent tumor, skin, visceral, and bone manifestations. Plexiform neurofibromas (PFNs), whether superficial or deep, affect 20 to 50 percent of patients and are responsible for significant morbidity. Inoperable, symptomatic PFNs can now be treated with targeted therapy (selumetinib) in both children and adults. Furthermore, NF1 patients frequently present with bone abnormalities, such as bone dysplasia, scoliosis, or reduced bone mineral density, suggesting impaired mineralization.

Inorganic pyrophosphate (PPi) is a potent antagonist of bone mineralization. It has been shown in a mouse model of NF1 and in human Schwann cell cultures derived from patients with NF1 (2 cases) that there is activation of genes regulating PPi homeostasis, particularly ANKH and ENPP1.

This study aims to measure plasma PPi levels in a cohort of patients with NF1 from the general population, based on their phenotype-specifically, the presence, location, and characteristics of NFPs-as well as their calcium and phosphorus levels.

02

Conditions studied

  • Neurofibromatosis 1 (NF1)
  • Plexiform Neurofibromas (NFP)

Keywords

  • pyrophosphate inorganique
  • Plasma
  • Imbalance
  • bone Remodelling Alterations
03

In context

Neurofibromatosis 1

177 studies on the registry are indexed under Neurofibromatosis 1; 44 are open to participants now.

This study's planned enrollment of 40 is below the median of 176 across 59 observational studies indexed under Neurofibromatosis 1.

Browse Neurofibromatosis 1 studies →

Lead sponsor

University Hospital, Angers is the lead sponsor of 481 studies on the registry; 123 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

40 patients. Age ≥18 years ; Confirmed diagnosis of NF1, based on current clinical and/or molecular criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Confirmed diagnosis of NF1, based on current clinical and/or molecular criteria
  • Consent obtained

Exclusion criteria

Exclusion Criteria:

  • Other condition affecting bone mineralization
  • Known severe renal insufficiency
  • Patient who refuses to participate in the study
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Diagnosed patients with NF1
06

What researchers measure

Primary outcomes

  1. PPi plasma concentration.

    Time frame: Visite 1

Secondary outcomes

  1. Plasma PPI Levels in NF1 patients

    Time frame: At the time of the consultation

  2. Urine PPI Levels in NF1 patients

    Time frame: At the time of the consultation

  3. presence of a plexiform neurofibroma in NF1 patients

    Time frame: At the time of the consultation

  4. presence of bone abnormalities in NF1 patients

    Time frame: At the time of the consultation

  5. Urinary PPI measurement in newly diagnosed patients with NF1

    Time frame: At the time of the consultation

  6. Location of plexiform neurofibromas

    Time frame: At the time of the consultation

  7. Calcium measurement

    Biological parameters of calcium-phosphorus metabolism (calcium, phosphorus, vitamin D, and PTH)

    Time frame: At the time of the consultation

  8. Phosporus measurement

    Biological parameters of calcium-phosphorus metabolism (calcium, phosphorus, vitamin D, and PTH)

    Time frame: At the time of the consultation

  9. Vitamine D Assay

    Biological parameters of calcium-phosphorus metabolism (calcium, phosphorus, vitamin D, and PTH)

    Time frame: At the time of the consultation

  10. Parathyroid hormone (PTH) measurement

    Biological parameters of calcium-phosphorus metabolism (calcium, phosphorus, vitamin D, and PTH)

    Time frame: At the time of the consultation

  11. Treatment with selumetinib

    Time frame: Visite 1

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2027; primary completion for Jun 2028, 14 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 18, 2026
StartEst.
Apr 9, 2027
Primary completionEst.
Jun 23, 2028
CompletionEst.
Jul 21, 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07944365
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Apr 9, 2027 (estimated)
Primary completion
Jun 23, 2028 (estimated)
Completion
Jul 21, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Issam BILAL, MS
Contact
Issam.Bilal@chu-angers.fr
+330241356828
Pauline BOITEZ, MD
principal investigator · University Hospital, Angers

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion